HeartSciences Inc. (HSCS) Cost of Revenue (2021 - 2025)

HeartSciences (HSCS) has reported Cost of Revenue for 5 consecutive years, with $1008.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue changed N/A year-over-year to $1008.0; the trailing twelve-month figure through Apr 2026 stood at $3648.0 (down 43.36% YoY), and the FY2026 full-year result was $1768.0, down 5.96% from the prior year.
• Cost of Revenue rose to $1008.0 in Q4 2025 per HSCS's latest filing, from $760.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $5756.0 in Q3 2021 and bottomed at $760.0 in Q1 2023.
• Historically, Cost of Revenue has averaged $2041.5 across 5 years, with a median of $1400.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue plunged 64.63% in 2022, then surged 500.13% in 2024.
• Over 5 years, Cost of Revenue stood at $5756.0 in 2021, then slumped by 64.63% to $2036.0 in 2022, then declined by 25.34% to $1520.0 in 2023, then surged by 200.07% to $4561.0 in 2024, then sank by 77.9% to $1008.0 in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1008.0, $760.0, and $1880.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.